for malignancy” in the cytologic diagnosis of solid pancreatic masses. Diagn Cytopathol 2014;42:292–296.
42Layfield LJ, Dodd L, Factor R, Schmidt RL: Malignancy risk associated with diagnostic categories defined by the Papanicolaou Society of Cytopathology pancreaticobiliary guidelines. Cancer Cytopathol 2014;122:420–427.
43Abdelgawwad MS, Alston E, Eltoum IA: The frequency and cancer risk associated with the atypical cytologic diagnostic category in endoscopic ultrasound-guided fine-needle aspiration specimens of solid pancreatic lesions: a meta-analysis and argument for a Bethesda system for reporting cytopathology of the pancreas. Cancer Cytopathol 2013;121:620–628.
44Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, Xie XJ, Schwarz RE: Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012;105:595–600.
45Yamaguchi K, Tanaka M; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of Japan Pancreas Society: EBM based clinical guidelines for pancreatic cancer 2009 from the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol 2011;41:836–840.
46Pancreatic Section of the British Society of Gastroenterology, Pancreatic Society of Great Britain and Ireland, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, Royal College of Pathologists, Special Interest Group for Gastro-Intestinal Radiology: Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005;54(suppl V):v1–v16.
47Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean G, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma Version 2.2017. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:1028–1061.
48Sturm PD, Hruban RH, Ramsoekh TB, Noorduyn LA, Tytgat GN, Gouma DJ, Offerhaus GJ: The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998;186:247–253.
49Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568–3573.
50Tada M, Ohashi M, Shiratori Y, Okudaira T, Komatsu Y, Kawabe T, Yoshida H, Machinami R, Kishi K, Omata M: Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996;110:227–231.
51Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y: Frequent c-K-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993;53:953–956.
52Terhune PG, Phifer DM, Tosteson TD, Longnecker DS: K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev 1998;7:515–521.
53Hruban RH, Wilentz RE, Kern SE: Genetic progression in the pancreatic ducts. Am J Pathol 2000;156:1821–1825.
54Levy MJ, Baron TH, Clayton AC, Enders FB, Gostout CJ, Halling KC, Kipp BR, Petersen BT, Roberts LR, Rumalla A, Sebo TJ, Topazian MD, Wiersema MJ, Gores GJ: Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008;103:1263–1273.
55Boldorini R, Paganotti A, Sartori M, Allegrini S, Miglio U, Orsello M, Veggiani C, Del Piano M, Monga G: Fluorescence in situ hybridisation in the cytological diagnosis of pancreatobiliary tumours. Pathology 2011;43:335–339.
56Barr Fritcher EG, Caudill JL, Blue JE, Djuric K, Feipel L, Maritim BK, Ragheb AA, Halling KC, Henry MR, Clayton AC: Identification of malignant cytologic criteria in pancreatobiliary brushings with corresponding positive fluorescence in situ hybridization results. Am J Clin Pathol 2011;136:442–449.
57Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, del Castillo CF, Warshaw AL: Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004;126:1330–1336.
58Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002–2006.
59Klimstra DS: Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. Semin Oncol 2013;40:23–36.
60Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B: Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 2011;108:21188–21193.
61Kanda M, Knight S, Topazian M, Syngal S, Farrell J, Lee J, Kamel I, Lennon AM, Borges M, Young A, Fujiwara S, Seike J, Eshleman J, Hruban RH, Canto MI, Goggins M: Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013;62:1024–1033.
Dr. Jasreman Dhillon
Moffitt Cancer Center
12902 USF Magnolia Drive
Tampa, FL 33612 (USA)
Published online: September 29, 2020
Centeno BA, Dhillon J (eds): Pancreatic Tumors. Monogr Clin Cytol. Basel, Karger, 2020, vol 26, pp 15–20 (DOI:10.1159/000455730)
______________________
Processing of Fine-Needle Aspiration Specimens from Pancreatic Lesions
Jasreman Dhillona, b
Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences and Pathology, University of South Florida, Tampa, FL, USA
______________________
Abstract
It is important to adequately process and triage the specimen obtained from fine-needle aspirations (FNAs) of pancreatic lesions. Many echo